Abbott Laboratories ABT
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -44.04% | -47.84% | -18.72% | -80.76% | -0.12% |
| Total Depreciation and Amortization | 58.79% | 36.42% | 6.22% | -1.86% | -1.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.17% | 18.31% | 9.69% | -69.98% | 2.56% |
| Change in Net Operating Assets | -348.28% | 151.00% | 7.45% | 107.33% | 64.54% |
| Cash from Operations | -37.67% | 21.54% | -7.20% | 15.59% | 3.03% |
| Capital Expenditure | -3.43% | 1.00% | 17.56% | 4.31% | 10.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -120.00% | -446.67% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 164.89% | 76.00% | -1,007.14% | -39.73% | 347.37% |
| Cash from Investing | 15.75% | -15.64% | -4,224.26% | -5.43% | 23.06% |
| Total Debt Issued | -- | 1,450.00% | 1,989,000.00% | 100.00% | -100.00% |
| Total Debt Repaid | -170.39% | -8,164.71% | -36.55% | 88.27% | -1,273.81% |
| Issuance of Common Stock | 44.93% | -91.43% | -59.58% | -80.00% | -25.00% |
| Repurchase of Common Stock | 96.39% | -17,316.67% | 35.71% | 4.13% | 59.39% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -6.11% | -7.09% | -7.02% | -7.52% | -7.40% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -36.65% | -220.69% | 942.48% | 24.93% | -11.68% |
| Foreign Exchange rate Adjustments | 110.00% | -92.16% | -195.83% | 107.23% | -127.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -287.86% | -505.49% | -58.58% | 1,643.10% | -1.93% |